Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors

Yan Chen; Xingguo Hou; Dapeng Li; Jin Ding; Jiayue Liu; Zilei Wang; Fei Teng; Hongjun Li; Fan Zhang; Yi Gu; Steven Yu; Xueming Qian; Zhi Yang; Hua Zhu

doi:10.1016/j.jpha.2023.02.011

Volume 13 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(4): 367-375

Yan Chen, Xingguo Hou, Dapeng Li, Jin Ding, Jiayue Liu, Zilei Wang, Fei Teng, Hongjun Li, Fan Zhang, Yi Gu, Steven Yu, Xueming Qian, Zhi Yang, Hua Zhu. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors[J]. Journal of Pharmaceutical Analysis, 2023, 13(4): 367-375. doi: 10.1016/j.jpha.2023.02.011

Citation:

Yan Chen, Xingguo Hou, Dapeng Li, Jin Ding, Jiayue Liu, Zilei Wang, Fei Teng, Hongjun Li, Fan Zhang, Yi Gu, Steven Yu, Xueming Qian, Zhi Yang, Hua Zhu. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors[J]. Journal of Pharmaceutical Analysis, 2023, 13(4): 367-375. doi: 10.1016/j.jpha.2023.02.011

Citation:

Yan Chen, Xingguo Hou, Dapeng Li, Jin Ding, Jiayue Liu, Zilei Wang, Fei Teng, Hongjun Li, Fan Zhang, Yi Gu, Steven Yu, Xueming Qian, Zhi Yang, Hua Zhu. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors[J]. Journal of Pharmaceutical Analysis, 2023, 13(4): 367-375. doi: 10.1016/j.jpha.2023.02.011

PDF( 2693 KB)

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors

doi: 10.1016/j.jpha.2023.02.011

Yan Chen^a,b,
Xingguo Hou^b,
Dapeng Li^a,b,
Jin Ding^b,
Jiayue Liu^b,
Zilei Wang^b,c,
Fei Teng^d,
Hongjun Li^d,
Fan Zhang^d,
Yi Gu^d,
Steven Yu^d,
Xueming Qian^{d
,
,},
Zhi Yang^{a,b,e
,
,},
Hua Zhu^{a,b,e
,
,}

a. Guizhou University Medicine College, Guiyang, 550025, China;
b. The Ministry of Education Key Laboratory of Carcinogenesis and Translational Research; NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China;
c. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, 646000, China;
d. Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, Jiangsu, 215127, China;
e. Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, 518055, China

Funds:

The research was funded by the National Natural Science Foundation of China (Grant Nos.: 82171973, 82171980, and 82102092) and Beijing Millions of Talent Projects A Level Funding (Grant No.: 2019A38). The study was also supported by Beijing Hospitals Authority Dengfeng Project (Grant No.: DFL20191102), the Pilot Project (4th Round) to Reform Public Development of Beijing Municipal Medical Research Institute (2021−1), and the Third Foster Plan in 2019 “Molecular Imaging Probe Preparation and Characterization of Key Technologies and Equipment” for the Development of Key Technologies and Equipment in Major Science and Technology Infrastructure in Shenzhen, China.

Received Date: Nov. 17, 2022
Accepted Date: Feb. 23, 2023
Rev Recd Date: Feb. 13, 2023
Publish Date: Feb. 28, 2023

Abstract

Abstract

Claudin18.2 (CLDN18.2) is a tight junction protein that is overexpressed in a variety of solid tumors such as gastrointestinal cancer and oesophageal cancer. It has been identified as a promising target and a potential biomarker to diagnose tumor, evaluate efficacy, and determine patient prognosis. TST001 is a recombinant humanized CLDN18.2 antibody that selectively binds to the extracellular loop of human Claudin18.2. In this study, we constructed a solid target radionuclide zirconium-89 (⁸⁹Zr) labled-TST001 to detect the expression of in the human stomach cancer BGC823^CLDN18.2 cell lines. The [⁸⁹Zr]Zr-desferrioxamine (DFO)-TST001 showed high radiochemical purity (RCP, >99%) and specific activity (24.15±1.34 GBq/μmol), and was stable in 5% human serum albumin, and phosphate buffer saline (>85% RCP at 96h). The EC₅₀ values of TST001 and DFO-TST001 were as high as 0.413±0.055 and 0.361±0.058nM(P>0.05), respectively. The radiotracer had a significantly higher average standard uptake values in CLDN18.2-positive tumors than in CLDN18.2-negative tumors (1.11±0.02 vs. 0.49±0.03, P=0.0016) 2 days post injection (p.i.). BGC823^CLDN18.2 mice models showed high tumor/muscle ratios 96h p.i. with [⁸⁹Zr]Zr-DFO-TST001 was much higher than those of the other imaging groups. Immunohistochemistry results showed that BGC823^CLDN18.2 tumors were highly positive (+++) for CLDN18.2, while those in the BGC823 group did not express CLDN18.2 (-). The results of exvivo biodistribution studies showed that there was a higher distribution in the BGC823^CLDN18.2 tumor bearing mice (2.05±0.16 %ID/g) than BGC823 mice (0.69±0.02 %ID/g) and blocking group (0.72±0.02 %ID/g). A dosimetry estimation study showed that the effective dose of [⁸⁹Zr]Zr-DFO-TST001 was 0.0705 mSv/MBq, which is within the range of acceptable doses for nuclear medicine research. Taken together, these results suggest that Good Manufacturing Practices produced by this immuno-positron emission tomography probe can detect CLDN18.2-overexpressing tumors.
- Claudin18.2,
- Gastrointestinal cancers,
- Zirconium-89,
- Positron emission tomography,
- Good Manufacturing Practices

FullText(HTML)

References(30)

References

H. Sung, J. Ferlay, R.L. Siegel, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71 (2021) 209-249.

W. Cao, H.-D. Chen, Y.-W. Yu, et al., Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020, Chin. Med. J (Engl). 134 (2021) 783-791.

H. Qiu, S. Cao, R. Xu, Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020, Cancer Commun (Lond). 41 (2021) 1037-1048.

Y.Y. Janjigian, K. Shitara, M. Moehler, et al., First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial, Lancet 398 (2021) 27-40.

E. Van Cutsem, V.M. Moiseyenko, S. Tjulandin, et al., Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J. Clin. Oncol. 24 (2006) 4991-4997.

K. Shitara, Chemotherapy for advanced gastric cancer: future perspective in Japan, Gastric Cancer 20 (2017) 102-110.

M. Pavel, K. Oberg, M. Falconi, et al., Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 31 (2020) 844-860.

L. Shen, Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges, Innovation (Camb). 3 (2022) 100249.

S. Tsukita, M. Furuse, M. Itoh, Multifunctional strands in tight junctions, Nat. Rev. Mol. Cell Biol. 2 (2001) 285-293.

D. Gunzel, A.S.L. Yu, Claudins and the modulation of tight junction permeability, Physiol. Rev. 93 (2013) 525-569.

T. Otani, M. Furuse, Tight Junction Structure and Function Revisited, Trends Cell Biol. 30 (2020) 805-817.

S. Tabaries, P.M. Siegel, The role of claudins in cancer metastasis, Oncogene 36 (2017) 1176-1190.

I. Hashimoto, T. Oshima, Claudins and gastric cancer: An overview, Cancers (Basel) 14 (2022) 290.

U. Sahin, O. Tureci, G. Manikhas, et al., FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma, Ann. Oncol. 32 (2021) 609-619.

J. Gong, N. Li, W. Guo, et al., American Society of Clinical Oncology Annual Meeting, June 01-02, 2022, Chicago IL, USA, pp. 4062-4062

C. Qi, J. Gong, J. Li, et al., Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results, Nat. Med. 28 (2022) 1189-1198.

L. Fan, X. Chong, M. Zhao, et al., Ultrasensitive gastric cancer circulating tumor cellular CLDN18.2 RNA detection based on a molecular beacon, Anal. Chem. 93 (2021) 665-670.

T. Gu, H. Shi, Relationship of 18F-FDG PET/CT parameters and CLDN 18.2 expression status in gastric cancer, J. Nucl. Med. 63 (2022) 3028-3028.

G. Hu, W. Zhu, Y. Liu, et al., Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study, Eur. J. Nucl. Med. Mol. Imaging. 49 (2022) 2634-2644.

G. Hu, W. Zhu, Y. Liu, et al., Study of 89Zr-labeled recombinant antibody VHH-Fc for noninvasive evaluation of CLDN18.2 expression in gastric cancer, J. Nucl. Med. 63 (2022) 2525-2525.

C. Zhao, Z. Rong, J. Ding, et al., Targeting Claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery, Mol. Pharm. 19 (2022) 3530-3541.

P.K.E. Borjesson, Y.W.S. Jauw, R. de Bree, et al., Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients, J. Nucl. Med. 50 (2009) 1828-1836.

R. Laforest, S.E. Lapi, R. Oyama, et al., [89Zr]Trastuzumab: Evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-Positive breast cancer, Mol. Imaging Biol. 18 (2016) 952-959.

J.A. O’Donoghue, J.S. Lewis, N. Pandit-Taskar, et al., Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-Trastuzumab in patients with esophagogastric cancer, J. Nucl. Med. 59 (2018) 161-166.

C.G. England, E.B. Ehlerding, R. Hernandez, et al., Preclinical pharmacokinetics and biodistribution studies of 89Zr-Labeled pembrolizumab, J. Nucl. Med. 58 (2017) 162-168.

N.B. Sobol, J.A. Korsen, A. Younes, K.J. Edwards, et al., Immuno-PET imaging of pancreatic tumors with 89Zr-Labeled gold nanoparticle-antibody conjugates, Mol. Imaging. Biol. 23 (2021) 84-94.

D. Vivier, S.K. Sharma, P. Adumeau, et al., The impact of FcγRI binding on immuno-PET, J. Nucl. Med. 60 (2019) 1174-1182.

P. Adumeau, R. Raave, M. Boswinkel, et al., Site-specific, platform-based conjugation strategy for the synthesis of dual-labeled immunoconjugates for bimodal PET/NIRF imaging of HER2-positive tumors, Bioconjug. Chem. 33 (2022) 530-540.

L.E. Lamberts, S.P. Williams, A.G.T. Terwisscha van Scheltinga, et al., Antibody positron emission tomography imaging in anticancer drug development, J. Clin. Oncol. 33 (2015) 1491-1504.

J. Zhang, R. Dong, L. Shen, Evaluation and reflection on Claudin 18.2 targeting therapy in advanced gastric cancer, Chin. J. Cancer Res. 32 (2020) 263-270.

Relative Articles

Supplements(0)

Cited By

Proportional views